Introduction
============

Myocardial infarction (MI), one of the leading cardiovascular diseases, may cause various complications, including cardiogenic shock, ventricular fibrillation, heart failure and recurrent ischemia ([@b1-mmr-19-05-3972]). The mortality rate in unselected patients with ST-segment elevation MI ranges between 6 and 14% in The European Society of Cardiology countries ([@b2-mmr-19-05-3972]). Physical examinations, highly sensitive biomarkers, electrocardiograms and imaging techniques are frequently used in the clinical diagnosis of MI. However, electrocardiograms were identified to be associated with low sensitivity ([@b2-mmr-19-05-3972]). Similarly, among the biomarkers for MI, the blood level of creatine kinase-muscle/brain (CK-MB) was identified to be associated with low specificity, ranging between 59.1 and 84.2% ([@b2-mmr-19-05-3972],[@b3-mmr-19-05-3972]). High-sensitivity cardiac muscle troponin T (TNNT) exhibited a limited specificity, ranging between 54 and 85% and a low positive predictive value of 61--87% ([@b4-mmr-19-05-3972]). Furthermore, various diseases, other than MI, may cause an increase in the circulating level of TNNT, including direct myocardial injury and various primary noncardiac diseases ([@b5-mmr-19-05-3972]). Additionally, the increase in TNNT2 blood plasma levels may be maintained for ≤2 weeks following MI ([@b6-mmr-19-05-3972]), thus, this parameter is not sufficient to monitor the disease status and the potential therapeutic effects of a treatment. Imaging techniques, including coronary computed tomography angiography, are alternative diagnostic methods; however, the iodinated contrast media used in coronary computed tomography angiography may lead to contrast-induced nephropathy ([@b7-mmr-19-05-3972]). Various protein biomarkers of MI have been identified in multiple previous studies ([@b8-mmr-19-05-3972],[@b9-mmr-19-05-3972]).

Over the past decade, multiple studies have used genomics, proteomics and metabolomics to identify sensitive and specific biomarkers for early diagnosis ([@b10-mmr-19-05-3972]--[@b16-mmr-19-05-3972]). Due to the improvements in mass spectrometry (MS) techniques, proteomics represents an efficient approach to investigate alterations in the expression levels of multiple proteins following the onset of MI. In 2003, Marshall *et al* ([@b10-mmr-19-05-3972]) used matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS and identified that fibrinogen peptide A and complement C3f peptide were cleaved by aminopeptidases in the serum of patients with MI. Following this previous study, various studies used proteomics analyses to identify biomarkers of MI via multiple technology platforms, including two-dimensional (2D) electrophoresis coupled with MALDI-TOF MS ([@b11-mmr-19-05-3972],[@b12-mmr-19-05-3972]), surface-enhanced laser desorption/ionization-TOF MS with ProteinChip arrays ([@b13-mmr-19-05-3972]) and liquid chromatography-tandem MS (LC-MS/MS) ([@b14-mmr-19-05-3972]--[@b16-mmr-19-05-3972]). The majority of previous studies analyzed blood samples ([@b12-mmr-19-05-3972],[@b16-mmr-19-05-3972]); however, purified platelets ([@b11-mmr-19-05-3972]) and cardiac tissues ([@b15-mmr-19-05-3972]) were additionally used to investigate biomarkers of MI, and multiple biomarkers were identified to be associated with the onset of MI.

Although the majority of previous studies analyzed serum to identify biomarkers of MI, blood serum remains challenging to investigate in proteomics analyses due to its dynamic range of abundant proteins and the complex composition of blood serum. Platelets and cardiac tissues are extracted proximally to the potential injury site, and various biomarkers were identified to be enriched in these samples ([@b14-mmr-19-05-3972]). However, platelets and cardiac samples are collected invasively. Therefore, these samples are not suitable for clinical experiments or for long-term monitoring. Urine composition is less complex than plasma and cardiac tissue, and its collection in large volumes is simple and noninvasive. Due to these characteristics, the urinary proteome was previously used to identify biomarkers of cardiovascular diseases, in particular for coronary artery disease (CAD) ([@b17-mmr-19-05-3972]--[@b20-mmr-19-05-3972]). A number of previous studies used capillary electrophoresis (CE)-MS to identify CAD-associated biomarkers. Previous clinical studies ([@b17-mmr-19-05-3972]--[@b19-mmr-19-05-3972]) performed CE-MS and identified various polypeptide panels used to differentiate between patients with CAD and healthy controls. In a previous animal model study, von zur Muhlen *et al* ([@b20-mmr-19-05-3972]) identified alterations in the protein expression levels of urinary polypeptides in apolipoprotein E mutant mice fed a high-fat diet compared with a standard diet. Collectively, these previously identified urinary polypeptide panels exhibited a sensitivity of 79--98% and a specificity of 83--100%. CE-MS allows the identification of urinary polypeptides; however, single proteins were not identified by these previous studies ([@b17-mmr-19-05-3972]--[@b20-mmr-19-05-3972]) and the characterization of the proteome of CAD remains limited. Additionally, these previous studies did not analyze the urinary proteome following surgical treatment and no biomarkers for monitoring therapeutic effects were identified. To the best of our knowledge, the present study is the first to use the isobaric tags for relative and absolute quantification (iTRAQ) technique to analyze the urinary proteome of patients with MI that underwent surgical treatment.

In the present study, the urinary proteome was analyzed within 12 h following the first symptoms of early-onset MI and at day 7 following percutaneous coronary intervention via iTRAQ labeling and 2D LC-MS/MS. The proteomes obtained were compared with normal healthy controls. The expression levels of the candidate biomarkers were further validated by multiple reaction monitoring (MRM) analysis using additional cohorts.

Patients and methods
====================

### Clinical samples

A total of 22 male patients with MI and 22 healthy male volunteers were included in the present study and were divided into two groups: Test group and validation group. In total, 7 male patients with MI and 7 healthy male volunteers were randomly included in the test group and were used for differential proteome analysis. Furthermore, 15 patients with MI and 15 healthy volunteers were included in the validation group used for MRM validation.

MI was diagnosed at The Fourth Affiliated Hospital of Jilin University (Changchun, China) between February 2011 and September 2011. The clinical characteristics of patient with MI are presented in [Table I](#tI-mmr-19-05-3972){ref-type="table"}. The age of patients with MI ranged between 41 and 59 years (mean age, 50.9 years; standard deviation of the mean age, 5.6 years). Patients with MI were excluded from the present study if any additional cardiovascular, renal or hepatic diseases were present. The patients with MI enrolled in the present study successfully underwent percutaneous coronary intervention (treatment group) 12 h following MI. The recanalization rate of the infarct-associated arteries was 100%, and the distal coronary flow was defined as 'thrombolysis in MI flow grade' 3, indicating a normal reflow ([@b21-mmr-19-05-3972]). Healthy volunteers (control group; age range, 44--59; mean age, 49.3 years; standard deviation of the mean age, 4.3 years), which were collected from 2012.04 to 2012.07, were considered healthy according to the clinical and electrocardiographic criteria used to diagnose the patients with MI. As the samples were collected for clinical examination and the present study analyzed the remaining parts of the samples, and the identity of the patients was anonymized throughout the study, the requirement for patient consent was waived by The Institutional Review Board of The Institute of Basic Medical Sciences (Beijing, China). The study was approved by The Institutional Review Board of The Institute of Basic Medical Sciences and followed the ethical guidelines of The Declaration of Helsinki ([@b22-mmr-19-05-3972]).

### Sample collection

Midstream urine samples were collected from healthy volunteers (control group) and patients with MI (treatment and MI group). For the MI group, urine samples were obtained from patients within 12 h of the first onset of MI. For the treatment group, urine samples were collected from patients with MI at 1 week following percutaneous coronary intervention (treatment group). Urine samples from individuals belonging to the same group (control, MI or treatment) were pooled to decrease individual variability. The samples were centrifuged at 3,500 × g at 4°C for 15 min. Subsequently, the cells and debris were removed. Clarified supernatants were stored at −80°C until further analysis.

### Urinary protein extraction

Urine samples were precipitated with ethanol at 4°C for 2 h, and proteins were collected by centrifugation at 12,000 × g for 30 min at 4°C. The pellets were resuspended in lysis buffer containing 7 M urea, 2 M thiourea, 0.1 M dithiothreitol (DTT) and 50 mM TBS. Following centrifugation at 12,000 × g for 30 min at 4°C, supernatants were collected. The protein concentration of each sample was determined using the Bradford method. The urine samples of the individuals belonging to the same group (control, MI and treatment) were pooled prior to further analysis.

### Protein digestion

The urinary proteins were digested via the filter-aided sample preparation approach combined with the microwave-assisted protein preparation method, according to a previous study ([@b23-mmr-19-05-3972]). The proteins were reduced with 20 mM DTT, alkylated with 50 mM 2-iodoacetamide on a 10 kDa filter and washed with urea solution (containing 8 M urea and 0.1 M TBS at pH 8.5) and 25 mM NH~4~HCO~3~. The trypsin-to-protein ratio was 1:50 and the samples were subjected to high-heat microwave oven irradiation for 1 min. Following digestion, the peptide mixtures were desalted with an octadecyl (C18) solid phase extraction column (Oasis HLB 3cc; 60 mg″ Extraction Cartridges; Waters Corporation, Milford, MA) according to the manufacturer\'s protocol.

### iTRAQ labeling

The digested peptides were labeled with the 4-plex iTRAQ reagent (SCIEX, Framingham, MA, USA). Equal quantities of control, MI, and treatment samples were mixed as an internal standard. The internal standard, control, MI and treatment samples were labeled with iTRAQ reagents 114, 115, 116 and 117, respectively. Labeling was performed according to the manufacturer\'s protocol (SCIEX). Subsequently, the four labeled protein samples were mixed in equal amounts and lyophilized.

### LC-MS/MS

The labeled samples were fractionated using a high-pH offline reversed-phase liquid chromatography (RPLC) column (column size, 4.6×250 mm; stationary phase, C18; pore size 3 µm; Waters Corporation). Pooled iTRAQ-labeled samples (200 µg) were loaded onto the column in buffer A1 (0.1% aqueous ammonia in water, pH 10) and eluted with buffer B1 (0.1% aqueous ammonia in 10% water and 90% acetonitrile; pH 10; flow rate, 0.8 ml/min) with a gradient ranging from 5--25% for 60 min at room temperature using a Water 2690 HPLC system (Waters Corporation). The eluted peptides were collected as 60 fractions, with one fraction collected per minute, and were pooled to obtain 20 samples.

Subsequently, each sample was analyzed by self-packing capillary online low-PH RPLC-MS/MS (column size, 75 µm ×100 mm; C18; pore size 3 µm). Samples (2 µl) were loaded onto the column in buffer A (0.1% formic acid in water) and eluted with buffer B (0.1% formic acid in acetonitrile; flow rate, 300 nl/min) with a gradient ranging from 5--25% for 60 min at room temperature using a Waters nanoAcquity system (Waters Corporation). A Triple TOF 5600 (SCIEX) was used to collect the MS data. The MS data were acquired using the following parameters: Positive ionization mode, nitrogen gas, flow rate (10 l/min), temperature, 150°C, nebulizer pressure, 10 psi, 30 data-dependent MS/MS scans per full scan, full scans acquired at a resolution of 40,000, MS/MS scans acquired at a resolution of 20,000, rolling collision energy, charge state screening (including precursors with +2 to +4 charge state), dynamic exclusion (exclusion duration 15 sec), an MS/MS scan range of 100--1800 m/z and a scan time of 100 msec. Each sample was run three times.

### Database searches

The MS/MS spectra were searched against the SwissProt human database ([www.uniprot.org](www.uniprot.org), 20,227 entries) using Mascot software (version 2.3.02; Matrix Science, Ltd., London, UK). The parent and fragment ion mass tolerances were 0.050 Da. The carbamidomethylation of cysteine was set as a fixed modification, and the number of miscleavage sites allowed was ≤2. Scaffold software (version Scaffold_4.0.7, Proteome Software, Inc., Portland, OR, USA) was used to filter the results. Protein identification was accepted at a false discovery rate (FDR) \<1.0% by analyzing the levels of proteins and peptides formed by ≥2 unique peptides. The identified proteins were quantified based on iTRAQ reporter ion intensities of unique peptides. The proteins containing quantification values in all channels in all three runs were considered suitable for quantification.

### Gene Ontology (GO) functional analysis

All differentially expressed proteins were assigned to their gene symbol according to the Panther database (<http://www.pantherdb.org/>) ([@b24-mmr-19-05-3972]). Protein classification was performed based on their functional annotation using GO according to the cellular components, molecular functions and biological processes. Multiple functional annotations were considered in the results.

### Ingenuity pathway analysis (IPA)

All differentially expressed proteins of the urinary proteomes were used for the pathway analysis. SwissProt accession numbers were used as inputs for the IPA software (version 2.3; Ingenuity Systems; Qiagen, Inc., Valencia, CA, USA). IPA software categorizes gene products based on the cellular compartments and indicates possible molecular, biochemical and biological functions. Based on the number of proteins associated with a certain pathway in the ingenuity pathway knowledge base, the significance of pathways was calculated using the right-tailed Fisher\'s exact test. The ratio of pathway enrichment was determined based on the proportion of differential proteins vs. the total number of proteins in a pathway.

### MRM

MRM was used to validate the differentially expressed proteins determined by iTRAQ. Data derived from a spectral library of the urinary proteomics generated by conventional LC-MS/MS using higher energy collision dissociation were imported into Skyline software (version 1.1; MacCoss Lab of Biological Mass Spectrometry; University of Washington, Seattle, WA, USA) ([@b25-mmr-19-05-3972]). The b and y ions exceeding the *m/z* ratio of the respective doubly and triply charged peptide precursors were considered in the analysis. In total, ≤5 transitions per peptide were traced on a QTRAP 6500 mass spectrometer (SCIEX) using the following parameters: Positive ionization mode, nitrogen gas, flow rate (10 l/min), temperature, 150°C, nebulizer pressure, 10 psi. The optimal peptides for MRM were selected using the following criteria: i) The peptide is unique to a protein; ii) the peptide does not contain methionine, asparagine or glutamine; iii) the peptide exhibits no trypsine-associated miscleavage sites. The details of the transitions (m/z) were presented in [Table II](#tII-mmr-19-05-3972){ref-type="table"}.

A total of 15 patients with MI and 15 healthy patients were used in the MRM confirmation group. In total, \~200 µg urine protein was digested in lysis buffer and centrifuged at 14,000 × g for 30 min at 4°C in an ultracentrifugation tube, in order to purify proteins \>10,000 Da. Samples (2 µg) were loaded onto a self-packed C18 RP capillary column (column size, 75 µm × 100 mm; C18; pore size 3 µm) with buffer A (0.1% formic acid + 99.9% H~2~O). The peptides were eluted with 5--30% buffer B (0.1% formic acid, 99.9% acetonitrile; flow rate, 300 nl/min) for 60 min at room temperature using an Eksigent nanoLC 400 system (SCIEX). Each sample was run three times. All MS data was imported into Skyline (version Scaffold_3.6.0; MacCoss Lab of Biological Mass Spectrometry; University of Washington), which was used for further visualization, transition detection and abundance calculations.

### Combined analysis of proteomics studies

To investigate proteins reported as differentially expressed in association with MI, the results from 14 previous proteomics studies, including those investigating expression in serum/plasma, tissue and platelets, were combined and analyzed, and compared with the findings of the urine analysis from the present study ([@b10-mmr-19-05-3972]--[@b16-mmr-19-05-3972],[@b26-mmr-19-05-3972]--[@b32-mmr-19-05-3972]).

### Statistical analysis

Statistical analyses were performed using the SPSS (version 19.0; IBM Corp., Armonk, NY, USA) statistical software. One-way analysis of variance (ANOVA) was used to analyze the LC-MS/MS results from control, MI and MI treatment groups, and to examine the significantly differentially expressed proteins. Following ANOVA, pairwise comparisons were performed using multiple t-tests with Bonferroni correction to investigate the proteins differentially expressed between the MI (or treatment) and control. The proteins of the urinary proteome exhibiting a fold change \>2 and P\<0.05 were considered differentially expressed. Proteins with a coefficient of variation (CV) \>0.3 were excluded from iTRAQ quantification. The MRM results for the control, MI and treatment groups were quantified and analyzed via ANOVA followed by a post hoc test with Bonferroni correction. Scatter plots were generated using Graphpad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA). In MRM analysis, the protein panels with a diagnostic potential identified following MRM verification were investigated via binary logistic regression analysis based on transition intensity, and receiver operating characteristic (ROC) curves were generated. The ROC curve was generated by plotting the true positive rate against the false positive rate at various threshold settings. The sensitivity and specificity for each patient and the ROC area under the curve (AUC) were calculated ([@b33-mmr-19-05-3972]). The correlation analysis was performed using Pearson\'s correlation test. The diagnostic sensitivity and specificity of each biomarker were obtained from the best operating point of the curve. The proteins exhibiting a ROC AUC \>0.8 were combined to calculate the total sensitivity and specificity for the diagnosis of MI ([@b34-mmr-19-05-3972]).

Results
=======

### Experimental design

The research design is presented in [Fig. 1](#f1-mmr-19-05-3972){ref-type="fig"}. MI urine samples were obtained from patients within 12 h of the first onset of MI (MI group). To obtain sensitive diagnostic biomarkers, urine samples from healthy volunteers were used as the control. To obtain biomarkers for monitoring the disease process and the therapeutic effect of the surgical treatment, urine samples were collected from patients with MI at 1 week after percutaneous coronary intervention (treatment group). The urine samples of the individuals belonging to the same group (control, MI or treatment) were pooled to decrease individual variability. High-pH offline RPLC and low-pH online RPLC-MS/MS techniques were used to increase the peptide separation efficiency. To obtain reliable quantitative results, each sample was analyzed three times. The differentially expressed proteins from the urinary proteomes were analyzed to identify potential biomarkers of MI. Differentially expressed proteins were analyzed using the combination of GO and IPA analyses, and the expression levels of the candidate biomarkers were confirmed by MRM analysis.

### Qualitative and quantitative results of the urinary proteome

In the analysis of the urinary proteome, 2,086 proteins were identified and the common ones (1,684) in three runs were used for quantification ([Table III](#tIII-mmr-19-05-3972){ref-type="table"}). To examine the repeatability of the present experimental results, the correlations between the normalized intensities from the quantified proteins of any two runs were analyzed ([Fig. 2](#f2-mmr-19-05-3972){ref-type="fig"}). The average Pearson correlation coefficient (R^2^) was 0.89, which suggested the reliability and the repeatability of the LC-MS/MS method. Additionally, the CVs of \~94% of the analyzed proteins were \<0.3. To obtain accurate quantitative results, proteins with a CV \>0.3 were excluded from the analysis of differentially expressed proteins. In total, 1,458 urinary proteins were used to screen the potential biomarkers associated with MI.

### Differentially expressed proteins in the urinary proteome

To define the threshold for differentially expressed proteins, the intrasample quantitative FDRs were calculated by comparing the quantitative results between any two runs within one sample. Following the analysis of proteins exhibiting a fold change \>2 in the urinary proteome, the resulting FDRs were 0%. Therefore, the thresholds selected to determine differentially expressed proteins in the urinary proteome were: Fold change \>2 and P\<0.05 (using a Bonferroni correction). The distributions of the total quantified proteins in the MI vs. control comparison and in the treatment vs. control comparison are presented as volcano plots of the corresponding fold change (log~2~ scale) against the transformed (-log~10~ scale) P-value in the urinary proteome ([Fig. 3A and B](#f3-mmr-19-05-3972){ref-type="fig"}). A total of 167 and 66 urinary proteins (data not shown) were defined as differentially expressed in the MI and treatment groups, respectively.

### GO annotation and IPA analysis

Data enrichment analysis was performed using IPA software and GO annotation. In the 'molecular function' category, the proteins enriched in the MI group exhibited 'receptor activity' and 'catalytic activity' functions ([Fig. 3C](#f3-mmr-19-05-3972){ref-type="fig"}). In the 'biological process' category, proteins involved in 'metabolic process' exhibited decreased levels of expression in the MI group compared with the treatment group, and the 'response to stimulus' term was enriched in the MI group ([Fig. 3D](#f3-mmr-19-05-3972){ref-type="fig"}). In the 'cellular component' category, differentially expressed proteins in the MI group were enriched in 'extracellular region' and 'membrane' compared with the treatment group ([Fig. 3E](#f3-mmr-19-05-3972){ref-type="fig"}). Affecting the levels of proteins in a certain subcellular localization and influencing the levels of proteins involved in a certain molecular function following MI may cause a dysregulation of the cellular metabolism, leading to pathological alterations.

IPA analysis suggested that eight pathways were significantly associated with MI vs. treatment ([Fig. 3F](#f3-mmr-19-05-3972){ref-type="fig"}). 'Acute phase response signaling' was the most enriched pathway in MI samples (P=1.73×10^−11^; ratio=0.086). The 'atherosclerosis signaling' pathway (P=8.90×10^−6^; ratio=0.0645) was enriched in the MI group; however, it was not significantly enriched in the treatment group (P=0.32; ratio=0.00806). Furthermore, coagulation-associated pathways, including the 'intrinsic prothrombin activation'(enrichment in the MI group: P=4.68×10^−3^; ratio=0.0732; enrichment in the treatment group: P=7.27×10^−3^; ratio=0.0488) and the 'extrinsic prothrombin activation' pathways (enrichment in the MI group: P=2.86×10^−4^; ratio=0.188), and cell metabolism-associated pathways, including the 'mitochondrial dysfunction' pathway (enrichment in the MI group: P=1.27×10^−8^; ratio=0.073; enrichment in the treatment group: P=1.49×10^−2^; ratio=0.018), exhibited an increased enrichment in the MI group compared with the treatment group (data not shown).

### Confirmation of differentially expressed proteins using MRM

According to IPA, the 'atherosclerosis signaling' pathway, coagulation-associated pathways and 'acute phase response' signaling pathway were involved in MI. Serum albumin (ALBU), antithrombin-III (ANT3), α-1-acid glycoprotein 1 (A1AG1), apolipoprotein A-I, complement C3 (CO3) and serum transferrin (TRFE) are important proteins in the identified pathways ([@b35-mmr-19-05-3972]--[@b41-mmr-19-05-3972]). Annexin A1 (ANXA1), neutrophil defensin 1 (DEF1) and intelectin-1 (ITLN1) were previously observed to be involved in the inflammatory response ([@b42-mmr-19-05-3972]--[@b45-mmr-19-05-3972]), and ANXA1 may have a role in the tissue damage and protection following ischemia-reperfusion (I/R) injury in the heart ([@b42-mmr-19-05-3972],[@b43-mmr-19-05-3972]). Protein δ homolog 1 (DLK1) is involved in the Notch pathway, affecting cardiac sympathetic reinnervation in rats following MI ([@b46-mmr-19-05-3972]). Small proline-rich protein 3 (SPRR3) and cathepsin Z (CATZ) were upregulated and downregulated in the MI group, respectively, and the protein expression levels of these two factors were restored following surgical treatment. However, to the best of our knowledge, the present study is the first to describe an association between these two proteins and MI.

The aforementioned 12 differentially expressed proteins were used for the MRM validation. In total, 16 peptides derived from these 12 proteins were analyzed using the MRM approach. The transition lists of all 16 peptides are presented in [Table II](#tII-mmr-19-05-3972){ref-type="table"}. The technical CVs were calculated for each peptide. The median technical CVs were 16.4, 10.0 and 11.1% in the control, MI and treatment groups, respectively, indicating high technical reproducibility ([Fig. 4A](#f4-mmr-19-05-3972){ref-type="fig"}). In total, four proteins (ALBU, ANT3, A1AG and SPRR3) presented two peptides each, and these eight peptides were used for MRM quantification. The two peptides corresponding to a single protein exhibited comparable expression levels in all three of the comparison groups ([Fig. 4B](#f4-mmr-19-05-3972){ref-type="fig"}). By plotting the transformed intensity (log~10~ scale) of the two peptides derived from a single protein in each sample, the R^2^ ranged between 0.81 and 0.95 for the four proteins analyzed ([Fig. 4C](#f4-mmr-19-05-3972){ref-type="fig"}). The present results suggested that the MRM quantification method exhibited high accuracy.

According to the sum of transition areas for every peptide, the relative intensities of peptides are presented as a scatter plot in [Fig. 5](#f5-mmr-19-05-3972){ref-type="fig"}. The protein expression levels of 16 peptides in patients with MI compared with the normal controls were consistent with the iTRAQ data for the 12 proteins analyzed (seven proteins were upregulated and five were downregulated; [Table IV](#tIV-mmr-19-05-3972){ref-type="table"}; [Fig. 5](#f5-mmr-19-05-3972){ref-type="fig"}).

Subsequently, the specificity and sensitivity of differentially expressed proteins as diagnostic biomarkers of MI were analyzed by binary logistic regression analysis based on the MRM data ([Table V](#tV-mmr-19-05-3972){ref-type="table"}). To increase the reliability of the diagnostic potential of the protein panel identified, ROC analysis was performed by combining all the urinary proteins with an AUC \>0.8 that exhibited a normal protein expression level following surgical treatment. ROC curves suggested that the combination of five proteins (ANT3, CO3, A1AG1, TRFE and CATZ) exhibited increased accuracy for MI diagnosis compared with the single proteins. The combination panel exhibited 94% sensitivity and 93% specificity, with an AUC of 0.95 ([Fig. 5F](#f5-mmr-19-05-3972){ref-type="fig"}).

TNNT2 is one of the most used biomarkers for MI, and high levels of TNNT2 are detectable for ≤2 weeks following MI ([@b6-mmr-19-05-3972]). In the present study, the expression levels of all five candidate biomarkers (ANT3, CO3, A1AG1, TRFE and CATZ) were identified to be notably decreased following treatment in iTRAQ and MRM quantification analysis. In total, the protein expression levels of three proteins (A1AG1, TRFE and CATZ) were significantly restored to normal levels following treatment compared with the MI group (P\<0.05) ([Table IV](#tIV-mmr-19-05-3972){ref-type="table"}). ANT3, CO3 and TRFE were restored to normal levels in 14 out of 16 patients; whereas A1AG1 in 13 out of 16 patients. Therefore, the identified candidate diagnostic biomarkers may be potentially used for monitoring the disease status and the potential therapeutic effects of a certain treatment.

Furthermore, a correlation analysis between the five proteins identified and a currently used biomarker, troponin I, cardiac muscle (TNNI3) ([@b47-mmr-19-05-3972]), was performed. CO3, ANT3 and TRFE exhibited a moderate positive correlation with the protein expression level of TNNI3 in patients with MI (R^2^=0.42, 0.43 and 0.32, respectively). A1AG1 and CATZ were not correlated with the protein expression levels of TNNI3 (R^2^=−0.14 and −0.11, respectively; data not shown). The present results suggested that the five urine biomarkers identified in the present study and TNNI3 may be associated with two distinct processes occurring in patients with MI. Additionally, the present results were compared with the results from previous studies using CE-MS ([Table VI](#tVI-mmr-19-05-3972){ref-type="table"}) ([@b17-mmr-19-05-3972]--[@b20-mmr-19-05-3972]). To further investigate the differentially expressed proteins associated with MI, 14 proteomics studies on MI were combined and analyzed, and 503 nonredundant biomarkers were identified, 456 of which were identified in the blood (data not shown). In addition, the present results were combined with previous studies, and 38 common proteins were identified. In total, 24 proteins exhibited a similar trend. A total of 696 proteins were identified to be differentially expressed in four types of samples, including cardiac tissues, platelets, blood and urine. The combined analysis suggested that the differentially expressed proteins from the four samples were distinct, and only 54 proteins were found in more than two samples ([Fig. 6A](#f6-mmr-19-05-3972){ref-type="fig"}). Furthermore, the differentially expressed proteins from four types of samples suggested various pathophysiological alterations ([Fig. 6B](#f6-mmr-19-05-3972){ref-type="fig"}). Biomarkers identified in blood were primarily involved in 'LXR/RXR activation', 'acute phase response signaling', 'clathrin-mediated endocytosis signaling', 'glycolysis' and 'atherosclerosis signaling'. Conversely, biomarkers identified in platelets were associated with alterations in 'epithelial adherens junction signaling', 'actin cytoskeleton' and 'integrin signaling' (data not shown). In addition to the enrichment of 'acute phase response signaling', 'LXR/RXR activation', 'coagulation system' and 'clathrin-mediated endocytosis signaling', the urine proteome exhibited alterations in 'mitochondrial dysfunction' and 'oxidative phosphorylation' pathways; however, no pathway was identified to be enriched in differential proteomes derived from cardiac tissues. Therefore, the urinary proteome may contain more information compared with the other three sample types, and it may be used to investigate intracellular and extracellular alterations.

Discussion
==========

In the present study, urinary proteomes were used to identify novel MI biomarkers. A total of 2,086 urinary proteins were identified. A total of 233 urinary proteins were differentially expressed. By performing IPA analysis, the 'atherosclerosis signaling' pathway was identified to be enriched in the urine of patients with MI, and it is associated with the pathology of MI. The 'acute phase response signaling' pathway was enriched in the urine of patients with MI, possibly due to the inflammatory response involved in MI, repair and remodeling ([@b48-mmr-19-05-3972]). The coagulation-associated pathways were enriched in the urine of patients with MI, possibly due to the thrombotic processes occurring in MI. Additionally, cell metabolism-associated pathways, including the 'mitochondrial dysfunction' and 'oxidative phosphorylation' pathways, were enriched in the urine of patients with MI. MI-induced prolonged ischemia in myocardial cells may lead to myocardial necrosis, resulting in dysfunctions of cell metabolism following MI ([@b48-mmr-19-05-3972]). In total, 12 differentially expressed proteins were validated by MRM analysis. Additionally, a panel of five proteins may be used to diagnose MI, since, in the present study, the combination of five biomarkers exhibited a sensitivity of 94% and a specificity of 93%, and these five proteins were identified to be restored following treatment.

CK-MB and TNNT2 are the most widely used MI biomarkers. However, CK-MB exhibits low specificity (0.591--0.842) ([@b2-mmr-19-05-3972],[@b3-mmr-19-05-3972]), similarly to TNNT2 (0.54--0.85), which exhibits high sensitivity and a low positive predictive value (0.61--0.87) ([@b4-mmr-19-05-3972]). In the present study, using iTRAQ quantification and MRM validation, 12 protein biomarkers for the early diagnosis of MI were identified. Notably, a five-protein panel containing ANT3, CO3, A1AG1, TRFE and CATZ exhibited 94% sensitivity and 93% specificity for the diagnosis of MI, with an AUC of \~0.95.

Among these 12 candidate biomarkers of MI, TRFE was observed to be differentially expressed in urine of patients with MI in a previous study ([@b49-mmr-19-05-3972]). In the present study, the protein expression levels of TRFE were identified to be increased in the urine of patients with MI, similarly to patients with coronary artery stenosis ([@b49-mmr-19-05-3972]) and in line with the serum levels of ischemic patients ([@b50-mmr-19-05-3972]). In the aforementioned panel, six proteins were previously identified to be differentially expressed in sera of patients with MI; however, to the best of our knowledge, the present study is the first to associate the urine levels of these proteins with MI. ALBU, ANT3, CO3 and A1AG1 were identified to be upregulated, and ANXA1 to be downregulated in the urine of patients with MI in the present study, in line with previous proteomic study results performed on sera ([@b8-mmr-19-05-3972],[@b13-mmr-19-05-3972],[@b14-mmr-19-05-3972],[@b16-mmr-19-05-3972],[@b26-mmr-19-05-3972]). APOA1 was identified to be upregulated in the urine of patients with MI in the present study, in line with the proteomics study performed on plasma samples by Keshishian *et al* ([@b16-mmr-19-05-3972]); however, this present results are in contrast with the study by Májek *et al* ([@b13-mmr-19-05-3972]). A previous study demonstrated that ANXA1 may protect from I/R injury in the heart ([@b42-mmr-19-05-3972]). ANXA1 binds to and activates proteins of the formyl peptide receptor family (a type of G protein-coupled receptor), which inhibits neutrophil activation, migration and infiltration ([@b43-mmr-19-05-3972]). A previous study investigating the cardioprotective actions of ANXA1 and its peptide mimetics examined its anti-inflammatory effects as a mechanism of preserving the viability of myocardial cells following I/R injury ([@b43-mmr-19-05-3972]).

In addition to the aforementioned seven proteins, five proteins were identified to be associated with MI in the present study, including DEF1, ITLN1, DLK1, SPRR3 and CATZ. DEF1 ([@b44-mmr-19-05-3972]), ITLN1 ([@b45-mmr-19-05-3972]) and DLK1 ([@b46-mmr-19-05-3972]) were demonstrated to be involved in the inflammatory response in previous studies. In the present study, DEF1 was identified to be decreased, and ITLN1 to be increased, following MI; however, the expression levels of these two proteins were not restored to normal levels following surgical treatment. Therefore, it was hypothesized that these inflammation-associated proteins may be involved in myocardial cell death following MI. DLK1 exhibited a decreased protein expression level in patients with MI and increased following treatment. DLK1 is an inhibitor of Notch signaling ([@b46-mmr-19-05-3972]). A previous study observed that the Notch signaling pathway may regulate macrophage-mediated inflammatory response, affecting cardiac sympathetic reinnervation in rats following MI ([@b51-mmr-19-05-3972]). Potentially, the decreased expression level of DLK1 may be associated with the regulation of the Notch signaling pathway during MI. SPRR3 was downregulated in the urine of patients with MI. SPRR3 belongs to the small proline-rich protein family and was identified to be associated with malignant tumorigenesis ([@b52-mmr-19-05-3972]). An increased expression level of CATZ was detected in MI urine samples in the present study. CATZ is a cysteine proteinase that exhibits carboxy-monopeptidase activities, and is involved in tumorigenesis ([@b53-mmr-19-05-3972]--[@b55-mmr-19-05-3972]). The molecular mechanism and the functions of these two proteins in myocardial infarction require further investigation.

TNNT2 is frequently used to diagnose MI, its protein expression level increases within 4--6 h after MI; however, the levels remain high for up to 2 weeks ([@b6-mmr-19-05-3972]) Therefore, TNNT2 is not a reliable marker for monitoring the MI disease status and the therapeutic effects of a treatment. Among the five novel protein biomarkers identified in the present study, the protein expression levels of two proteins increased to normal levels; however, not significantly. By contrast, the expression levels of three other proteins was significantly restored to normal levels by 7 days after treatment. These three proteins may exhibit a diagnostic potential for early MI with high sensitivity and specificity, and may be additionally used for monitoring the MI disease status and the therapeutic effects of a certain treatment. Further studies are required to investigate the diagnostic potential of these proteins in monitoring the effects of a certain treatment on the MI status by comparing an effective treatment with an ineffective treatment.

A number of previous studies ([@b17-mmr-19-05-3972]--[@b20-mmr-19-05-3972]) used the CE-MS approach to find CAD-associated biomarkers in urine. These previous studies identified polypeptide panels able to distinguish patients with CAD and normal controls in both clinical samples and animal models and the panels of biomarkers identified exhibited 79--98% sensitivity and 83--100% specificity. The present study used iTRAQ technology to identify and validate a five-protein panel with 94% sensitivity and 93% specificity, results in line with the previous studies using CE-MS. CE-MS approach is able to selectively identify urinary polypeptides derived from a protein and these polypeptide may be indirectly associated with the pathology of MI. The present study used the urinary proteome based on iTRAQ technology to identify differentially expressed proteins following MI. The protein identified may be directly associated with the pathological alterations of MI. Using CE-MS, nine common proteins were identified in previous studies ([@b17-mmr-19-05-3972]--[@b20-mmr-19-05-3972]) \[collagen α-1(I) chain, collagen α-1(III) chain, α-1-antitrypsin, granin-like neuroendocrine peptide precursor, membrane-associated progesterone receptor component 1, sodium/potassium-transporting adenosine triphosphatase γ chain, fibrinogen-α chain, epidermal growth factor and kidney androgen-regulated protein\]. The present study identified 233 differentially expressed proteins in patients with MI. Notably, only one protein was identified in the present study and in the previous CE-MS-based studies, indicating that the urine peptidome and proteome may be used to investigate distinct aspects of MI.

In addition, significant differences were identified between proteomes derived from various types of tissues. Therefore, a comprehensive study of the MI proteome from multiple sources may facilitate the identification of sensitive and specific diagnostic biomarkers. The present results suggested that the urinary proteome may be associated with pathophysiological alterations caused by MI and may provide useful diagnostic insights. The candidate biomarkers identified in the urinary proteome may be used for the early diagnosis of MI and to monitor the MI disease status and the therapeutic effect of a certain treatment. Collectively, the present study may facilitate the application of the urinary proteome to diagnose MI.
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![Workflow of the proteomics experiment using iTRAQ labeling and 2D LC-MS/MS for biomarker identification and verification. Urine samples collected within 12 h of first-onset MI, 1 week following surgical treatment and from seven healthy subjects were digested and pooled using equal amounts of each sample to generate an internal standard. Following iTRAQ labeling, urinary peptides were analyzed by 2D-LC-MS three times. The MS results were analyzed using the Swiss-Prot human database to obtain quantitative data. Gene ontology analysis and IPA were performed to identify pathological alterations associated with MI. Selected differentially expressed proteins were further validated by MRM analysis. iTRAQ, isobaric tags for relative and absolute quantitation; 2D, two-dimensional; LC, liquid chromatography; MS, mass spectrometry; MS/MS, tandem MS; MI, myocardial infarction; RP, reversed-phase; RPLC, reversed-phase liquid chromatography; TOF, time of flight; IPA, ingenuity pathway analysis; MRM, multiple reaction monitoring.](MMR-19-05-3972-g00){#f1-mmr-19-05-3972}

![Normalized intensity scatter plots of two representative analyses of urine samples from the control, myocardial infarction and treatment groups.](MMR-19-05-3972-g01){#f2-mmr-19-05-3972}

![Analysis of differentially expressed proteins in urine. Quantitative analysis of urine samples from the (A) MI and (B) treatment groups. Volcano plot indicating transformed P-value (-log~10~) against the log~2~ fold change in three groups of urine samples. Data enrichment analysis of differentially expressed proteins using gene ontology according to their (C) molecular function, (D) biological progress and (E) cellular component. (F) Ingenuity pathway analysis results for the MI and treatment groups. The 8 most enriched pathways are ranked according to their significance score of the MI group. The X-axis indicates the probability of the enrichment of a certain pathway, corrected for multiple comparisons using Fisher\'s exact test with a threshold value of 0.05. MI, myocardial infarction.](MMR-19-05-3972-g02){#f3-mmr-19-05-3972}

![Accuracy of MRM quantification. (A) Technical CV of 16 peptides in the three groups. N=18/group. Data are presented as the mean ± standard error of the mean. \*P\<0.05. (B) Peptides derived from the same proteins exhibit similar quantification trends among the three groups. N=15, 16 and 16 for control, MI and treatment groups, respectively. Data are presented as the mean ± standard deviation. (C) Correlation analysis of the transformed intensities (log~10~) of the two peptides plotted in each sample. CV, coefficient of variation; MI, myocardial infarction; ALBU, albumin; A1AG1, α-1-acid glycoprotein 1; ANT3, antithrombin-III; SPRR3, small proline-rich protein 3.](MMR-19-05-3972-g03){#f4-mmr-19-05-3972}

![Multiple reaction monitoring results for differentially expressed proteins in urine samples. Scatter plots demonstrating the MRM quantification results in the control, MI and treatment groups for (A) ANT3, (B) CO3, (C) A1AG1, (D) TRFE and (E) CATZ. (F) ROC curve analysis was performed by combining the differential expression levels of five proteins in urine to discriminate between patients with MI and healthy controls. (G) Scatter plots of 11 peptides for the control, MI and treatment groups. Data are presented as the mean ± standard error of the mean. N=15, 16 and 16 for the control, MI and treatment groups, respectively. \*P\<0.05, \*P\<0.01, \*\*\*P\<0.001. ANT3, antithrombin-III; CO3, complement C3; A1AG1, α-1-acid glycoprotein 1; MI, myocardial infarction; TRFE, serum transferrin; CATZ, cathepsin Z; ROC, receiver operating characteristic; ALBU, albumin; APOA1, apolipoprotein A-I; ANXA1, Annexin A 1; DEF1, neutrophil defensin 1; SPRR3, small proline-rich protein 3; DLK1, protein δ homolog 1; ITLN1, intelectin-1.](MMR-19-05-3972-g04){#f5-mmr-19-05-3972}

![Candidate biomarkers in the present study and previous studies. (A) Venn diagram indicating the proteins differentially expressed following MI in urine from the present study and blood, platelet and cardiac tissue samples from previous studies. (B) Ingenuity pathway analysis of MI-associated regulatory pathways affected in urine samples and previously reported blood, platelet and cardiac tissue samples. MI, myocardial infarction; LXR, liver X receptors; RXR, retinoid X receptor; FXR, farnesoid X receptor.](MMR-19-05-3972-g05){#f6-mmr-19-05-3972}

###### 

Clinical characteristics of male patients with myocardial infarction.

  A, Samples used for isobaric tags for relative and absolute quantitation analysis                     
  ----------------------------------------------------------------------------------- ----------------- ------------------------------------------------------------------------------
  1                                                                                   42                Anterior, inferior and right ventricular myocardial infarction; hypertension
  2                                                                                   47                Anterior myocardial infarction
  3                                                                                   48                Inferior and right ventricular myocardial infarction; hypertension
  4                                                                                   48                Anterior myocardial infarction
  5                                                                                   51                Inferior and right ventricular myocardial infarction; hypertension
  6                                                                                   57                Inferior and posterior myocardial infarction
  7                                                                                   57                Anterior and inferior myocardial infarction; hypertension
                                                                                                        
  **B, Samples used for multiple reaction monitoring analysis**                                         
                                                                                                        
  **Patient ID**                                                                      **Age (years)**   **Diagnosis**
                                                                                                        
  8                                                                                   56                Anterior myocardial infarction; hypertension; stomach cancer
  9                                                                                   49                Anterior myocardial infarction; hepatitis C virus
  10                                                                                  48                Anterior myocardial infarction
  11                                                                                  51                Anterior myocardial infarction
  12                                                                                  54                Inferior and posterior myocardial infarction; hypertension
  13                                                                                  58                Anterior myocardial infarction
  14                                                                                  59                Anterior and inferior myocardial infarction
  15                                                                                  41                Inferior and posterior myocardial infarction; hypertension
  16                                                                                  41                Anterior myocardial infarction
  17                                                                                  47                Inferior myocardial infarction
  18                                                                                  48                inferior and right ventricular Myocardial infarction; hypertension
  19                                                                                  50                Anterior myocardial infarction; hypertension
  20                                                                                  52                Anterior, inferior and right ventricular myocardial infarction; hypertension
  21                                                                                  58                Anterior and right ventricular myocardial infarction; hypertension
  22                                                                                  58                Inferior myocardial infarction; hypertension

###### 

Transition for multiple reaction monitoring analysis.

  Transition                                                MS           MS/MS         Time    DP     CE
  --------------------------------------------------------- ------------ ------------- ------- ------ ------
  sp\|P02768\|ALBU_HUMAN.DLGEENFK.+2y6.light                476.224539   723.330795    24.18   65.8   26.0
  sp\|P02768\|ALBU_HUMAN.DLGEENFK.+2y5.light                476.224539   666.309331    24.18   65.8   26.0
  sp\|P02768\|ALBU_HUMAN.DLGEENFK.+2y4.light                476.224539   537.266738    24.18   65.8   26.0
  sp\|P02768\|ALBU_HUMAN.DLGEENFK.+2y3.light                476.224539   408.224145    24.18   65.8   26.0
  sp\|P02768\|ALBU_HUMAN.DLGEENFK.+2y2.light                476.224539   294.181218    24.18   65.8   26.0
  sp\|P02768\|ALBU_HUMAN.LVNEVTEFAK.+2y9.light              575.311146   1036.530952   30.25   73.1   29.6
  sp\|P02768\|ALBU_HUMAN.LVNEVTEFAK.+2y8.light              575.311146   937.462538    30.25   73.1   29.6
  sp\|P02768\|ALBU_HUMAN.LVNEVTEFAK.+2y7.light              575.311146   823.41961     30.25   73.1   29.6
  sp\|P02768\|ALBU_HUMAN.LVNEVTEFAK.+2y6.light              575.311146   694.377017    30.25   73.1   29.6
  sp\|P02768\|ALBU_HUMAN.LVNEVTEFAK.+2y5.light              575.311146   595.308603    30.25   73.1   29.6
  sp\|P01008\|ANT3_HUMAN.LPGIVAEGR.+2y8.light               456.269084   798.446828    25.63   64.4   25.3
  sp\|P01008\|ANT3_HUMAN.LPGIVAEGR.+2y7.light               456.269084   701.394064    25.63   64.4   25.3
  sp\|P01008\|ANT3_HUMAN.LPGIVAEGR.+2y6.light               456.269084   644.3726      25.63   64.4   25.3
  sp\|P01008\|ANT3_HUMAN.LPGIVAEGR.+2y5.light               456.269084   531.288536    25.63   64.4   25.3
  sp\|P01008\|ANT3_HUMAN.LPGIVAEGR.+2y4.light               456.269084   432.220122    25.63   64.4   25.3
  sp\|P01008\|ANT3_HUMAN.DDLYVSDAFHK.+2b3.light             655.306592   344.145226    29.82   78.9   32.4
  sp\|P01008\|ANT3_HUMAN.DDLYVSDAFHK.+2y8.light             655.306592   966.467957    29.82   78.9   32.4
  sp\|P01008\|ANT3_HUMAN.DDLYVSDAFHK.+2y7.light             655.306592   803.404629    29.82   78.9   32.4
  sp\|P01008\|ANT3_HUMAN.DDLYVSDAFHK.+2y6.light             655.306592   704.336215    29.82   78.9   32.4
  sp\|P01008\|ANT3_HUMAN.DDLYVSDAFHK.+2y4.light             655.306592   502.277243    29.82   78.9   32.4
  sp\|P01024\|CO3_HUMAN.DFDFVPPVVR.+2y8.light               595.813856   928.525078    42.82   74.6   30.3
  sp\|P01024\|CO3_HUMAN.DFDFVPPVVR.+2y7.light               595.813856   813.498135    42.82   74.6   30.3
  sp\|P01024\|CO3_HUMAN.DFDFVPPVVR.+2y6.light               595.813856   666.429721    42.82   74.6   30.3
  sp\|P01024\|CO3_HUMAN.DFDFVPPVVR.+2y5.light               595.813856   567.361307    42.82   74.6   30.3
  sp\|P01024\|CO3_HUMAN.DFDFVPPVVR.+2y4.light               595.813856   470.308544    42.82   74.6   30.3
  sp\|P02763\|A1AG1_HUMAN.TEDTIFLR.+2y7.light               497.763831   893.472708    30.96   67.4   26.8
  sp\|P02763\|A1AG1_HUMAN.TEDTIFLR.+2y6.light               497.763831   764.430115    30.96   67.4   26.8
  sp\|P02763\|A1AG1_HUMAN.TEDTIFLR.+2y5.light               497.763831   649.403172    30.96   67.4   26.8
  sp\|P02763\|A1AG1_HUMAN.TEDTIFLR.+2y4.light               497.763831   548.355494    30.96   67.4   26.8
  sp\|P02763\|A1AG1_HUMAN.TEDTIFLR.+2y3.light               497.763831   435.27143     30.96   67.4   26.8
  sp\|P02763\|A1AG1_HUMAN.SDVVYTDWK.+2y7.light              556.766571   910.466895    29.91   71.7   28.9
  sp\|P02763\|A1AG1_HUMAN.SDVVYTDWK.+2y6.light              556.766571   811.398481    29.91   71.7   28.9
  sp\|P02763\|A1AG1_HUMAN.SDVVYTDWK.+2y5.light              556.766571   712.330067    29.91   71.7   28.9
  sp\|P02763\|A1AG1_HUMAN.SDVVYTDWK.+2y4.light              556.766571   549.266738    29.91   71.7   28.9
  sp\|P02763\|A1AG1_HUMAN.SDVVYTDWK.+2y3.light              556.766571   448.219060    29.91   71.7   28.9
  sp\|P04083\|ANXA1_HUMAN.GLGTDEDTLIEILASR.+2y10.light      851.946523   1130.641565   49.31   93.2   39.5
  sp\|P04083\|ANXA1_HUMAN.GLGTDEDTLIEILASR.+2y9.light       851.946523   1015.614622   49.31   93.2   39.5
  sp\|P04083\|ANXA1_HUMAN.GLGTDEDTLIEILASR.+2y8.light       851.946523   914.566943    49.31   93.2   39.5
  sp\|P04083\|ANXA1_HUMAN.GLGTDEDTLIEILASR.+2y7.light       851.946523   801.482879    49.31   93.2   39.5
  sp\|P04083\|ANXA1_HUMAN.GLGTDEDTLIEILASR.+2y6.light       851.946523   688.398815    49.31   93.2   39.5
  sp\|P59665\|DEF1_HUMAN.IPAC\[CAM\]IAGER.+2y8.light        493.758026   873.424713    21.87   67.1   26.6
  sp\|P59665\|DEF1_HUMAN.IPAC\[CAM\]IAGER.+2y7.light        493.758026   776.371949    21.87   67.1   26.6
  sp\|P59665\|DEF1_HUMAN.IPAC\[CAM\]IAGER.+2y6.light        493.758026   705.334835    21.87   67.1   26.6
  sp\|P59665\|DEF1_HUMAN.IPAC\[CAM\]IAGER.+2y5.light        493.758026   545.304186    21.87   67.1   26.6
  sp\|P59665\|DEF1_HUMAN.IPAC\[CAM\]IAGER.+2y4.light        493.758026   432.220122    21.87   67.1   26.6
  sp\|P02787\|TRFE_HUMAN.DGAGDVAFVK.+2y8.light              489.748181   806.440680    25.92   66.8   26.5
  sp\|P02787\|TRFE_HUMAN.DGAGDVAFVK.+2y7.light              489.748181   735.403566    25.92   66.8   26.5
  sp\|P02787\|TRFE_HUMAN.DGAGDVAFVK.+2y6.light              489.748181   678.382102    25.92   66.8   26.5
  sp\|P02787\|TRFE_HUMAN.DGAGDVAFVK.+2y5.light              489.748181   563.355159    25.92   66.8   26.5
  sp\|P02787\|TRFE_HUMAN.DGAGDVAFVK.+2y4.light              489.748181   464.286745    25.92   66.8   26.5
  sp\|Q9UBC9\|SPRR3_HUMAN.VPEPGYTK.+2y7.light               445.734543   791.393395    17.23   63.6   24.9
  sp\|Q9UBC9\|SPRR3_HUMAN.VPEPGYTK.+2y6.light               445.734543   694.340632    17.23   63.6   24.9
  sp\|Q9UBC9\|SPRR3_HUMAN.VPEPGYTK.+2y5.light               445.734543   565.298038    17.23   63.6   24.9
  sp\|Q9UBC9\|SPRR3_HUMAN.VPEPGYTK.+2y4.light               445.734543   468.245275    17.23   63.6   24.9
  sp\|Q9UBC9\|SPRR3_HUMAN.VPEPGYTK.+2y3.light               445.734543   411.223811    17.23   63.6   24.9
  sp\|Q9UBC9\|SPRR3_HUMAN.VPVPGYTK.+2y7.light               430.747453   761.419216    20.95   62.5   24.4
  sp\|Q9UBC9\|SPRR3_HUMAN.VPVPGYTK.+2y6.light               430.747453   664.366452    20.95   62.5   24.4
  sp\|Q9UBC9\|SPRR3_HUMAN.VPVPGYTK.+2y5.light               430.747453   565.298038    20.95   62.5   24.4
  sp\|Q9UBC9\|SPRR3_HUMAN.VPVPGYTK.+2y4.light               430.747453   468.245275    20.95   62.5   24.4
  sp\|Q9UBC9\|SPRR3_HUMAN.VPVPGYTK.+2y3.light               430.747453   411.223811    20.95   62.5   24.4
  sp\|Q8WWA0\|ITLN1_HUMAN.EWTC\[CAM\]SSSPSLPR.+2y10.light   703.822083   1091.514984   31.53   82.4   34.2
  sp\|Q8WWA0\|ITLN1_HUMAN.EWTC\[CAM\]SSSPSLPR.+2y9.light    703.822083   990.467306    31.53   82.4   34.2
  sp\|Q8WWA0\|ITLN1_HUMAN.EWTC\[CAM\]SSSPSLPR.+2y8.light    703.822083   830.436657    31.53   82.4   34.2
  sp\|Q8WWA0\|ITLN1_HUMAN.EWTC\[CAM\]SSSPSLPR.+2y7.light    703.822083   743.404629    31.53   82.4   34.2
  sp\|Q8WWA0\|ITLN1_HUMAN.EWTC\[CAM\]SSSPSLPR.+2y6.light    703.822083   656.372600    31.53   82.4   34.2
  sp\|Q9UBR2\|CATZ_HUMAN.VGDYGSLSGR.+2y9.light              505.748713   911.421735    21.84   68.0   27.1
  sp\|Q9UBR2\|CATZ_HUMAN.VGDYGSLSGR.+2y8.light              505.748713   854.400272    21.84   68.0   27.1
  sp\|Q9UBR2\|CATZ_HUMAN.VGDYGSLSGR.+2y7.light              505.748713   739.373329    21.84   68.0   27.1
  sp\|Q9UBR2\|CATZ_HUMAN.VGDYGSLSGR.+2y6.light              505.748713   576.310000    21.84   68.0   27.1
  sp\|Q9UBR2\|CATZ_HUMAN.VGDYGSLSGR.+2y5.light              505.748713   519.288536    21.84   68.0   27.1
  sp\|P80370\|DLK1_HUMAN.C\[CAM\]PAGFIDK.+2y7.light         454.220745   747.403566    21.96   64.2   25.2
  sp\|P80370\|DLK1_HUMAN.C\[CAM\]PAGFIDK.+2y6.light         454.220745   650.350802    21.96   64.2   25.2
  sp\|P80370\|DLK1_HUMAN.C\[CAM\]PAGFIDK.+2y5.light         454.220745   579.313689    21.96   64.2   25.2
  sp\|P80370\|DLK1_HUMAN.C\[CAM\]PAGFIDK.+2y3.light         454.220745   375.223811    21.96   64.2   25.2
  sp\|P80370\|DLK1_HUMAN.C\[CAM\]PAGFIDK.+2y2.light         454.220745   262.139747    21.96   64.2   25.2
  sp\|P02647\|APOA1_HUMAN.DLATVYVDVLK.+2y9.light            618.347715   1007.577354   44.71   76.2   31.1
  sp\|P02647\|APOA1_HUMAN.DLATVYVDVLK.+2y9.light            618.347715   1007.577354   44.71   76.2   31.1
  sp\|P02647\|APOA1_HUMAN.DLATVYVDVLK.+2y9.light            618.347715   1007.577354   44.71   76.2   31.1
  sp\|P02647\|APOA1_HUMAN.DLATVYVDVLK.+2y9.light            618.347715   1007.577354   44.71   76.2   31.1
  sp\|P02647\|APOA1_HUMAN.DLATVYVDVLK.+2y9.light            618.347715   1007.577354   44.71   76.2   31.1

MS, mass spectrometry; MS/MS, tandem MS; DP, declustering potentials; CE, collision energies; CATZ, cathepsin Z; ITLN1, intelectin-1; ALBU, albumin; DLK1, protein δ homolog 1; SPRR3, small proline-rich protein 3; ANT3, antithrombin-III; CO3, complement C3; A1AG1, α-1-acid glycoprotein 1; TRFE, serum transferrin; DEF1, neutrophil defensin 1; ANXA1, Annexin A 1, APOA1, apolipoprotein A-I.

###### 

Numbers of identified proteins, peptides, spectrums and the average numbers of identifications for three analyses.

  A, Qualitative analysis                                                     
  ------------------------------------- ------------------ ------------------ --------------
  Total number                          2,086              14,780             117062
  Average identification of three run   2,005              10,926               39021
                                                                              
  **B, Quantitative analysis**                                                
                                                                              
  **Measurement**                       **Proteins (n)**   **Peptides (n)**   **Spectrum**
                                                                              
  Total no.                             1,684              13,358             111006
  Average identification of three run   1,684              10,032               37604

###### 

Validation of marker candidates by MRM analysis. Comparison between MRM and iTRAQ data.

  Protein symbol                                                                                         Uniprot accession number   Peptide sequence   iTRAQ, fold change MI/control   MRM, fold change MI/control                             iTRAQ, fold change MI/treat   MRM, fold change MI/treat                              Frequency of patients exhibiting a significant different level of the protein
  ------------------------------------------------------------------------------------------------------ -------------------------- ------------------ ------------------------------- ------------------------------------------------------- ----------------------------- ------------------------------------------------------ -------------------------------------------------------------------------------
  ALBU^[b](#tfn3-mmr-19-05-3972){ref-type="table-fn"}^                                                   P02768                     DLGEENFK           2.47                            4.99^[c](#tfn4-mmr-19-05-3972){ref-type="table-fn"}^    2.00                          4.23^[c](#tfn4-mmr-19-05-3972){ref-type="table-fn"}^   14/16
  ALBU^[b](#tfn3-mmr-19-05-3972){ref-type="table-fn"}^                                                   P02768                     LVNEVTEFAK         2.47                            5.68^[d](#tfn5-mmr-19-05-3972){ref-type="table-fn"}^    2.00                          2.90^[c](#tfn4-mmr-19-05-3972){ref-type="table-fn"}^   14/16
  ANT3^[a](#tfn2-mmr-19-05-3972){ref-type="table-fn"},[b](#tfn3-mmr-19-05-3972){ref-type="table-fn"}^    P01008                     LPGIVAEGR          5.33                            6.93^[c](#tfn4-mmr-19-05-3972){ref-type="table-fn"}^    4.00                          2.51                                                   14/16
  ANT3^[a](#tfn2-mmr-19-05-3972){ref-type="table-fn"},[b](#tfn3-mmr-19-05-3972){ref-type="table-fn"}^    P01008                     DDLYVSDAFHK        5.33                            6.62^[c](#tfn4-mmr-19-05-3972){ref-type="table-fn"}^    4.00                          2.32                                                   14/16
  CO3^[a](#tfn2-mmr-19-05-3972){ref-type="table-fn"},[b](#tfn3-mmr-19-05-3972){ref-type="table-fn"}^     P01024                     DFDFVPPVVR         2.33                            15.80^[c](#tfn4-mmr-19-05-3972){ref-type="table-fn"}^   2.80                          2.68                                                   14/16
  APOA1^[b](#tfn3-mmr-19-05-3972){ref-type="table-fn"}^                                                  P02647                     DLATVYVDVLK        2.65                            14.27^[c](#tfn4-mmr-19-05-3972){ref-type="table-fn"}^   3.75                          2.78                                                   13/16
  A1AG1^[a](#tfn2-mmr-19-05-3972){ref-type="table-fn"},[b](#tfn3-mmr-19-05-3972){ref-type="table-fn"}^   P02763                     TEDTIFLR           2.05                            6.02^[d](#tfn5-mmr-19-05-3972){ref-type="table-fn"}^    1.28                          2.04^[c](#tfn4-mmr-19-05-3972){ref-type="table-fn"}^   13/16
  A1AG1^[a](#tfn2-mmr-19-05-3972){ref-type="table-fn"},[b](#tfn3-mmr-19-05-3972){ref-type="table-fn"}^   P02763                     SDVVYTDWK          2.10                            6.47^[d](#tfn5-mmr-19-05-3972){ref-type="table-fn"}^    1.30                          1.86                                                   13/16
  ANXA1                                                                                                  P04083                     GLGTDEDTLIEILASR   0.38                            0.74                                                    1.50                          0.91                                                   10/16
  DEF1                                                                                                   P59665                     IPACIAGER          0.46                            0.56                                                    1.71                          0.81                                                   7/16
  TRFE^[a](#tfn2-mmr-19-05-3972){ref-type="table-fn"},[b](#tfn3-mmr-19-05-3972){ref-type="table-fn"}^    P02787                     DGAGDVAFVK         2.56                            6.30^[d](#tfn5-mmr-19-05-3972){ref-type="table-fn"}^    2.56                          3.08^[c](#tfn4-mmr-19-05-3972){ref-type="table-fn"}^   14/16
  SPRR3                                                                                                  Q9UBC9                     VPEPGYTK           0.46                            0.10                                                    0.96                          0.64                                                   8/16
  SPRR3                                                                                                  Q9UBC9                     VPVPGYTK           0.46                            0.17                                                    0.96                          0.98                                                   6/16
  CATZ^[a](#tfn2-mmr-19-05-3972){ref-type="table-fn"},[b](#tfn3-mmr-19-05-3972){ref-type="table-fn"}^    Q9UBR2                     VGDYGSLSGR         2.41                            4.70^[e](#tfn6-mmr-19-05-3972){ref-type="table-fn"}^    1.71                          1.68^[c](#tfn4-mmr-19-05-3972){ref-type="table-fn"}^   6/16
  DLK1                                                                                                   P80370                     CPAGFIDK           0.49                            0.86                                                    0.65                          0.65                                                   7/16
  ITLN1                                                                                                  AQ8WW0                     EWTCSSSPSLPR       2.93                            2.80^[d](#tfn5-mmr-19-05-3972){ref-type="table-fn"}^    1.46                          0.86                                                   10/16

Protein of the panel for early diagnosis

Proteins restored to normal expression levels following surgical treatment.

P\<0.05

P\<0.01

P\<0.001. MRM, multiple reaction monitoring; iTRAQ, isobaric tags for relative and absolute quantitation; ALBU, albumin; ANT3, antithrombin-III; CO3, complement C3; APOA1, apolipoprotein A-I; A1AG1, α-1-acid glycoprotein 1; ANXA1, Annexin A 1; DEF1, neutrophil defensin 1; TRFE, serum transferrin; SPRR3, small proline-rich protein 3; CATZ, cathepsin Z; DLK1, protein δ homolog 1; ITLN1, intelectin-1.

###### 

Sensitivity, specificity and receiver operating characteristic AUC values for urinary proteins.

  Protein symbol                                   Accession no.   Peptide sequence   Sensitivity   Specificity   AUC
  ------------------------------------------------ --------------- ------------------ ------------- ------------- ------
  ALBU                                             P02768          DLGEENFK           0.69          0.87          0.78
  ALBU                                             P02768          LVNEVTEFAK         0.69          0.93          0.80
  ANT3                                             P01008          LPGIVAEGR          1.00          0.67          0.89
  ANT3                                             P01008          DDLYVSDAFHK        0.88          0.87          0.88
  CO3                                              P01024          DFDFVPPVVR         0.69          0.93          0.86
  A1AG1                                            P02647          TEDTIFLR           0.88          0.73          0.86
  A1AG1                                            P02763          SDVVYTDWK          0.81          0.87          0.90
  APOA1                                            P04083          GLGTDEDTLIEILASR   0.25          0.73          0.40
  DEF1                                             P59665          IPACIAGER          0.81          0.47          0.60
  TRFE                                             P02787          DGAGDVAFVK         0.81          0.93          0.90
  SPRR3                                            Q9UBC9          VPEPGYTK           0.63          0.40          0.38
  SPRR3                                            Q9UBC9          VPVPGYTK           0.88          0.33          0.44
  CATZ                                             Q9UBR2          VGDYGSLSGR         0.69          0.93          0.84
  DLK1                                             P80370          CPAGFIDK           0.38          0.80          0.45
  ITLN1                                            Q8WWA0          EWTCSSSPSLPR       0.56          0.80          0.80
  ANXA1                                            P04083          GLGTDEDTLIEILASR   0.25          0.73          0.40
  Combination of ANT3, CO3, A1AG1, TRFE and CATZ                                      0.94          0.93          0.95

AUC, area under the curve; ALBU, albumin; ANT3, antithrombin-III; CO3, complement C3; A1AG1, α-1-acid glycoprotein 1; APOA1, apolipoprotein A-I; DEF1, neutrophil defensin 1; TRFE, serum transferrin; SPRR3, small proline-rich protein 3; CATZ, cathepsin Z; DLK1, protein δ homolog 1; ITLN1, intelectin-1, ANXA1, Annexin A 1.

###### 

Comparison between the proteins identified in the present study and the proteins significantly upregulated in previous capillary electrophoresis-mass spectrometry studies.

  Protein name                                                       Uniprot accession number   Differentially expressed in the present study
  ------------------------------------------------------------------ -------------------------- -----------------------------------------------
  Collagen α-1(I) chain                                              P02452                     No
  Collagen α-1(III) chain                                            P02461                     No
  α-1-antitrypsin                                                    P01009                     No
  Granin-like neuroendocrine peptide precursor                       Q9UHG2                     No
  Membrane-associated progesterone receptor component 1              O00264                     No
  Sodium/potassium-transporting adenosine triphosphatase subunit γ   P57410                     No
  Fibrinogen α chain                                                 P02671                     No
  Pro-epidermal growth factor                                        P01133                     Yes, upregulated
  Kidney androgen-regulated protein                                  P61110                     No

[^1]: Contributed equally
